Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2017-03-03 Legal Proceedings Report
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Announces That Its Licensee Janssen Has Reported New Data From Two Phase 3 Studies of Guselkumab in Plaque Psoriasis (news with additional features)
Legal Proceedings Report Classification · 99% confidence The document is a news release dated March 3, 2017, originating from MorphoSys AG via DGAP (a service often used for regulatory news dissemination). The content announces that MorphoSys's licensee, Janssen, reported new data from Phase 3 studies of Guselkumab. It explicitly mentions that the results were included in Janssen's 'regulatory filings of guselkumab in the US and Europe.' The document itself is an announcement about clinical trial results and licensing activity, not the full financial report (10-K), an interim report (IR), or a formal earnings release (ER). Since it is a corporate announcement disseminated through a regulatory news service (DGAP) that doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Capital Change (CAP), the most appropriate general category for a corporate news announcement that isn't a specific report type is Regulatory Filings (RNS). It is not a Report Publication Announcement (RPA) because it is reporting substantive news (study results), not just announcing the publication of a separate report.
2017-03-03 English
Invitation to Year-End Results 2016 Conference Call
Report Publication Announcement Classification · 99% confidence The document is titled "Invitation to Year-End Results 2016 Conference Call" and explicitly states that MorphoSys AG "will publish its Annual Financial Results 2016 on March 9, 2017." The core content is an invitation, including the date, time, and dial-in numbers for a conference call where management will present these results. This structure—announcing the release of results and inviting participants to the subsequent discussion—is characteristic of an Earnings Release (ER) or, more specifically, an announcement leading up to the discussion of those results. Since the document is an invitation to discuss the *Year-End Results* (which would typically be contained in a 10-K or a detailed ER), and it is focused on the conference call event itself, it strongly aligns with the definition of an Earnings Release (ER) which covers the initial announcement of periodical financial results and associated calls. It is not the full 10-K, nor is it just the transcript (CT). It is the announcement/invitation for the results presentation.
2017-03-02 English
MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
Regulatory Filings Classification · 100% confidence The document is a press release dated February 21, 2017, announcing that MorphoSys's subsidiary Lanthio Pharma has initiated a Phase 1 clinical study for a new compound, MOR107. It details the study's goals (safety, tolerability, PK/PD) and provides background on the technology and pipeline. This type of announcement, focusing on clinical trial initiation and pipeline progress, is typically classified as a general corporate news release or an announcement related to R&D/pipeline updates. Since there is no specific category for 'Clinical Trial Initiation' and it is not a full Earnings Release (ER), Interim Report (IR), or Annual Report (10-K), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate news that doesn't fit the highly specific financial or governance categories. It is not a report itself, but an announcement of an event/study start, and it is too detailed to be a simple Report Publication Announcement (RPA).
2017-02-21 English
District Court Grants MorphoSys's Request to Add Second Patent in Lawsuit
Legal Proceedings Report Classification · 99% confidence The document is a news release dated February 15, 2017, detailing a legal development where MorphoSys AG successfully added a second patent to its lawsuit against Janssen Biotech and Genmab A/S regarding patent infringement. This content specifically relates to significant lawsuits and regulatory actions involving the company. This aligns directly with the definition for Legal Proceedings Report (LTR). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific legal matter.
2017-02-15 English
MorphoSys to Present at Upcoming Conference
Regulatory Filings Classification · 100% confidence The document is a short news release dated February 10, 2017, announcing that MorphoSys AG will present at the LEERINK Partners 6th Annual Global Healthcare Conference on February 16, 2017. It provides details about the presenter, date, venue, and links to where the presentation PDF and webcast will be available. Since this is an announcement about an upcoming presentation at a conference, and not the presentation itself, the most appropriate classification is 'Investor Presentation' (IP) if the content were the presentation slides, or, given the nature of the announcement itself (a brief notice about an event where a presentation will occur), it fits best under a general regulatory/news announcement category. However, since the document explicitly states that a PDF version of the presentation *will be provided* at a link, and the core subject is the company's participation in a conference where they will present, it strongly relates to investor communication about future strategy/pipeline. If the document were the actual presentation slides, it would be IP. As it is a notice about the event, and it is not a standard financial report (10-K, IR, ER), it is a general corporate announcement. Given the options, and recognizing this is a notice about an investor event, it is closest to Investor Presentation (IP) or a general Regulatory Filing (RNS). Since it is a specific announcement about an investor-facing event, and not a mandatory regulatory filing like a 10-K or a dividend notice, I will check the definitions. It is not an Earnings Release (ER) or a Call Transcript (CT). It is an announcement about an event where an Investor Presentation will be given. If the document were the presentation itself, it would be IP. As it is a notice *about* the presentation, it functions as a general corporate news item. Given the options, and the fact that it is a specific announcement about an investor event, I will lean towards the most specific relevant category, which is often used for such announcements, or the fallback. Since it is a specific announcement about an investor event, and not a mandatory filing, I will classify it as a general Regulatory Filing (RNS) as it is a standard news release disseminated via DGAP, unless the presentation itself is attached or the focus is purely on the presentation content (which it is not, it's an announcement of attendance). Given the context of investor relations announcements, and the lack of a specific 'Conference Presentation Announcement' code, RNS is the safest fallback for non-standard news releases. However, if we interpret 'Investor Presentation' (IP) broadly to include announcements *about* investor presentations, that might fit. Let's re-evaluate: It is a news release announcing participation in a conference where a presentation will be given. This is a common type of investor relations communication. Since the document is short and announces where the presentation materials will be found, it is very close to an RPA, but RPA is for announcing the *publication* of a report. This announces an *event*. Therefore, RNS (Regulatory Filings / General News) is the most appropriate general category for this specific type of corporate news release that doesn't fit the core financial report types.
2017-02-10 English
Report Publication Announcement 2017
Report Publication Announcement Classification · 100% confidence The document is titled "Preliminary announcement of the publication of quarterly reports and quarterly/interim statements" by MorphoSys AG. It explicitly states that it is announcing *when* future financial reports (Quarterly/Interim statements) will be disclosed, providing future dates (May 03, 2017, and November 07, 2017) and links to where they will be available. This fits the definition of announcing the timing or release of a report, which corresponds to the Report Publication Announcement (RPA) code. The document length (1705 chars) is short, supporting the 'announcement of a report' classification rather than the report itself.
2017-02-01 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.